228 related articles for article (PubMed ID: 12940594)
1. Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure.
Põder P; Eha J; Sundberg S; Antila S; Heinpalu M; Loogna I; Planken U; Rantanen S; Lehtonen L
Int J Clin Pharmacol Ther; 2003 Aug; 41(8):365-73. PubMed ID: 12940594
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study.
Põder P; Eha J; Sundberg S; Antila S; Heinpalu M; Loogna I; Planken U; Rantanen S; Lehtonen L
J Clin Pharmacol; 2004 Oct; 44(10):1143-50. PubMed ID: 15342615
[TBL] [Abstract][Full Text] [Related]
3. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.
Sundberg S; Antila S; Scheinin H; Häyhä M; Virtanen M; Lehtonen L
Int J Clin Pharmacol Ther; 1998 Dec; 36(12):629-35. PubMed ID: 9876999
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan.
Antila S; Kivikko M; Lehtonen L; Eha J; Heikkilä A; Pohjanjousi P; Pentikäinen PJ
Br J Clin Pharmacol; 2004 Apr; 57(4):412-5. PubMed ID: 15025738
[TBL] [Abstract][Full Text] [Related]
5. Orally available levosimendan dose-related positive inotropic and lusitropic effect in conscious chronically instrumented normal and heart failure dogs.
Masutani S; Cheng HJ; Hyttilä-Hopponen M; Levijoki J; Heikkilä A; Vuorela A; Little WC; Cheng CP
J Pharmacol Exp Ther; 2008 Apr; 325(1):236-47. PubMed ID: 18174383
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):465-71. PubMed ID: 12395979
[TBL] [Abstract][Full Text] [Related]
7. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up.
Sargento L; Brito D; Matias JS; Madeira H
Rev Port Cardiol; 2007; 26(7-8):717-26. PubMed ID: 17939581
[TBL] [Abstract][Full Text] [Related]
9. Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity.
Graudins A; Najafi J; Rur-SC MP
Clin Toxicol (Phila); 2008 Jan; 46(1):50-6. PubMed ID: 17926153
[TBL] [Abstract][Full Text] [Related]
10. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
[TBL] [Abstract][Full Text] [Related]
11. The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects.
Lehtonen L; Sundberg S
Eur J Clin Pharmacol; 2002 Oct; 58(7):449-52. PubMed ID: 12389066
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
[TBL] [Abstract][Full Text] [Related]
13. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
Cleland JG; Nikitin N; McGowan J
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
[TBL] [Abstract][Full Text] [Related]
14. The effect of levosimendan during long-term amiodarone treatment in dogs.
Papp JG; Pollesello P; Varró A; Végh A; Udvary E
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):27-32. PubMed ID: 16867167
[TBL] [Abstract][Full Text] [Related]
15. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
[TBL] [Abstract][Full Text] [Related]
16. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone.
Nanas JN; Papazoglou PP; Terrovitis JV; Kanakakis J; Dalianis A; Tsolakis E; Tsagalou EP; Agrios N; Christodoulou K; Anastasiou-Nana MI
Am J Cardiol; 2004 Nov; 94(10):1329-32. PubMed ID: 15541261
[TBL] [Abstract][Full Text] [Related]
18. The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure.
Harjola VP; Oikarinen L; Toivonen L; Jurkko R; Puttonen J; Sarapohja T; Sundberg S; Nieminen MS
Int J Clin Pharmacol Ther; 2008 Aug; 46(8):389-99. PubMed ID: 18793580
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
Nanas JN; Papazoglou P; Tsagalou EP; Ntalianis A; Tsolakis E; Terrovitis JV; Kanakakis J; Nanas SN; Alexopoulos GP; Anastasiou-Nana MI
Am J Cardiol; 2005 Mar; 95(6):768-71. PubMed ID: 15757608
[TBL] [Abstract][Full Text] [Related]
20. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies.
Lilleberg J; Ylönen V; Lehtonen L; Toivonen L
Scand Cardiovasc J; 2004 May; 38(2):80-4. PubMed ID: 15204232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
